Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson Sells 6,528 Shares

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 6,528 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the sale, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

John Bradley Sorenson also recently made the following trade(s):

• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Stock Up 0.9 %

Shares of BSX stock opened at $106.15 on Tuesday. The company has a 50 day simple moving average of $94.88 and a two-hundred day simple moving average of $87.28. The stock has a market cap of $156.44 billion, a P/E ratio of 84.92, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12 month low of $64.54 and a 12 month high of $107.17. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Piper Sandler raised their price target on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. UBS Group raised their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Friday. Barclays upped their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank of Canada raised their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Finally, Citigroup upped their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $107.39.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BSX. TFC Financial Management Inc. raised its stake in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 210 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Boston Scientific in the third quarter worth $28,000. Dunhill Financial LLC lifted its stake in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 152 shares in the last quarter. Global Wealth Strategies & Associates lifted its stake in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares in the last quarter. Finally, West Oak Capital LLC purchased a new stake in Boston Scientific in the 4th quarter worth $29,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.